Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer

Androgen deprivation therapy (ADT) is the foundation of treatment for patients with locally advanced, recurrent and metastatic prostate cancer, most commonly using luteinizing releasing hormone (LHRH) agonists. More recently, a new approach to ADT has emerged with the development of gonadotropin-rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Saad, Fred, Shore, Neal D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366106/
https://www.ncbi.nlm.nih.gov/pubmed/34408793
http://dx.doi.org/10.1177/1758835921998586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366106/
https://www.ncbi.nlm.nih.gov/pubmed/34408793
http://dx.doi.org/10.1177/1758835921998586

Ejemplares similares